Mirum Pharmaceuticals, Inc. Share-based Payment Arrangement, Amount Capitalized
Mirum Pharmaceuticals, Inc. (MIRM) reported Share-based Payment Arrangement, Amount Capitalized of $700.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes
us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount · last filed 2026-02-25
- Mirum Pharmaceuticals, Inc. share-based payment arrangement, amount capitalized for the quarter ending 2025-12-31 was $200.00K, a 0.00% change year-over-year.
- Mirum Pharmaceuticals, Inc. share-based payment arrangement, amount capitalized for the quarter ending 2025-09-30 was $200.00K, a 0.00% change year-over-year.
- Mirum Pharmaceuticals, Inc. share-based payment arrangement, amount capitalized for the quarter ending 2025-06-30 was $100.00K, a 80.00% decline year-over-year.
- Mirum Pharmaceuticals, Inc. share-based payment arrangement, amount capitalized for the quarter ending 2025-03-31 was $200.00K, a 0.00% change year-over-year.
- Mirum Pharmaceuticals, Inc. share-based payment arrangement, amount capitalized for fiscal 2025 was $700.00K, a 36.36% decline from fiscal 2024.
- Mirum Pharmaceuticals, Inc. share-based payment arrangement, amount capitalized for fiscal 2024 was $1.10M, a 37.50% increase from fiscal 2023.
- Mirum Pharmaceuticals, Inc. share-based payment arrangement, amount capitalized for fiscal 2023 was $800.00K, a 100.00% increase from fiscal 2022.
- Mirum Pharmaceuticals, Inc. share-based payment arrangement, amount capitalized for fiscal 2022 was $400.00K, a 300.00% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Amount Capitalized 3 month | Share-based Payment Arrangement, Amount Capitalized 6 month | Share-based Payment Arrangement, Amount Capitalized 9 month | Share-based Payment Arrangement, Amount Capitalized 12 month |
|---|---|---|---|---|
| 2025-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $400.00K derived: sum of 2 quarters · filed 2026-02-25 | $500.00K derived: sum of 3 quarters · filed 2026-02-25 | $700.00K 10-K · filed 2026-02-25 |
| 2025-09-30 | $200.00K 10-Q · filed 2025-11-04 | $300.00K derived: sum of 2 quarters · filed 2025-11-04 | $500.00K 10-Q · filed 2025-11-04 | $700.00K derived: sum of 4 quarters · filed 2026-02-25 |
| 2025-06-30 | $100.00K 10-Q · filed 2025-08-06 | $300.00K 10-Q · filed 2025-08-06 | $500.00K derived: sum of 3 quarters · filed 2026-02-25 | $700.00K derived: sum of 4 quarters · filed 2026-02-25 |
| 2025-03-31 | $200.00K 10-Q · filed 2025-05-07 | $400.00K derived: sum of 2 quarters · filed 2026-02-25 | $600.00K derived: sum of 3 quarters · filed 2026-02-25 | $1.10M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $400.00K derived: sum of 2 quarters · filed 2026-02-25 | $900.00K derived: sum of 3 quarters · filed 2026-02-25 | $1.10M 10-K · filed 2026-02-25 |
| 2024-09-30 | $200.00K 10-Q · filed 2025-11-04 | $700.00K derived: sum of 2 quarters · filed 2025-11-04 | $900.00K 10-Q · filed 2025-11-04 | $1.10M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $500.00K 10-Q · filed 2025-08-06 | $700.00K 10-Q · filed 2025-08-06 | $900.00K derived: sum of 3 quarters · filed 2026-02-25 | $1.10M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $200.00K 10-Q · filed 2025-05-07 | $400.00K derived: sum of 2 quarters · filed 2026-02-25 | $600.00K derived: sum of 3 quarters · filed 2026-02-25 | $800.00K derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $400.00K derived: sum of 2 quarters · filed 2026-02-25 | $600.00K derived: sum of 3 quarters · filed 2026-02-25 | $800.00K 10-K · filed 2026-02-25 |
| 2023-09-30 | $200.00K 10-Q · filed 2024-11-12 | $400.00K derived: sum of 2 quarters · filed 2024-11-12 | $600.00K 10-Q · filed 2024-11-12 | $700.00K derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $200.00K 10-Q · filed 2024-08-07 | $400.00K 10-Q · filed 2024-08-07 | $500.00K derived: sum of 3 quarters · filed 2025-02-26 | $700.00K derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $200.00K 10-Q · filed 2024-05-08 | $300.00K derived: sum of 2 quarters · filed 2025-02-26 | $500.00K derived: sum of 3 quarters · filed 2025-02-26 | $700.00K derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $300.00K derived: sum of 2 quarters · filed 2025-02-26 | $500.00K derived: sum of 3 quarters · filed 2025-02-26 | $400.00K 10-K · filed 2025-02-26 |
| 2022-09-30 | $200.00K 10-Q · filed 2023-11-02 | $400.00K derived: sum of 2 quarters · filed 2023-11-02 | $300.00K 10-Q · filed 2023-11-02 | |
| 2022-06-30 | $200.00K 10-Q · filed 2023-08-07 | $200.00K 10-Q · filed 2023-08-07 | ||
| 2022-03-31 | $200.00K 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | $100.00K 10-K · filed 2024-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |